Management
Board of Directors
George Golumbeski, PhD
Chairman of the Board and Former Executive Vice President of Business Development for Celgene
George Golumbeski has more than 30 years of experience in the biotechnology industry. He has a long history of forging collaborations with companies engaged in “cutting edge” science. Currently he is dedicated to working to develop young companies. He is a partner at DROIA Ventures. He currently serves on the Board of Directors of Carrick Therapeutics, Sage Therapeutics, and MorphoSys. George was most recently Executive Vice President of Business Development for Celgene, where he was responsible for forging collaborations with biotechnology companies seeking to bring breakthrough medications to people suffering from cancer and chronic inflammation. He holds a PhD in Genetics from the University of Wisconsin-Madison, and conducted his post-doctoral research in molecular biology at the University of Colorado-Boulder. George holds a bachelor’s degree in biology from the University of Virginia
Helen M. Boudreau
Former COO of the Bill & Melinda Gates Medical Research Institute
Helen has 30 years of experience across the biotech, pharmaceuticals, consulting and banking industries. Helen was most recently COO of the Bill & Melinda Gates Medical Research Institute, a non-profit biotech focused on diseases that cause mortality, poverty and inequality in low- and middle-income countries. Previously, she served as CFO for public and private biotechs, and served in senior finance roles at Novartis and Pfizer, including CFO for Novartis Global Oncology. Helen is currently a member of the board of Premier, Inc. (NASDAQ: PINC), a healthcare improvement company, and is also on the boards of two private biotech companies. Helen earned a BA in Economics, summa cum laude, from the University of Maryland, and an MBA from the Darden Graduate School of Business at the University of Virginia.
Neil Gibson, PhD
Chief Scientific Officer, Biologics, COI Pharma
Neil has over 25 years of drug development experience and currently serves as chief scientific officer, biologics at COI Pharmaceuticals, where he is responsible for the creation of novel drug discovery companies based on innovative and disruptive technologies. Neil has over 25 years of drug development experience and currently serves as chief scientific officer, biologics at COI Pharmaceuticals, where he is responsible for the creation of novel drug discovery companies based on innovative and disruptive technologies. Neil has held various senior positions within the biotechnology and pharmaceutical industry including senior vice president, BioAtla; chief scientific officer, Regulus Therapeutics; chief scientific officer and oncology therapeutic area head, Pfizer Oncology; and chief scientific officer, OSI Pharmaceuticals. While at Pfizer, Neil was also a member of the Pfizer Oncology Business Unit Executive team. Neil has been involved in the successful discovery, development, and commercialization of four approved oncology drugs, including temozolomide, sorafenib, erlotinib, and crizotinib. While at Regulus he was responsible for leading all research and development efforts resulting in three distinct oligonucleotides being advanced into clinical development and the establishment of human proof of concept with the lead molecule RG-101. Neil has held numerous academic appointments, including associate professor, School of Pharmacy and Comprehensive Cancer Center, University of Southern California, and Fogarty Fellow at the National Cancer Institute, National Institutes of Health. During his career, he has served on the Experimental Therapeutics Study Section of the National Cancer Institute and has been actively involved with the American Association of Cancer Research. He is also a past president of the British Pharmaceutical Students Association. Neil earned his Ph.D. in 1982 from the University of Aston in Birmingham, England.
Taylor H. Schreiber, MD, PhD
Chief Executive Officer and Co-founder
Taylor is a co-founder of Shattuck Labs and currently serves as Chief Executive Officer and a member of the Board of Directors. Before his appointment as CEO in January 2020, Taylor served as the company’s Chief Scientific Officer. Taylor is the lead inventor of Shattuck’s ARC technology platform. Prior to Shattuck, he served as Chief Scientific Officer of Heat Biologics, Inc. where he was a co-inventor of significant elements of Heat’s ImPACT and ComPACT technology platforms. Taylor was also the co-inventor of Pelican Therapeutics ‘s TNFRSF25 agonist technology where he served as Chairman of the Scientific Advisory Board. Taylor has numerous publications in the field of tumor immunology and immunotherapy, spanning the subjects of cancer vaccines, therapeutic proteins and antibodies, adenosinergic and IDO mediated immunosuppression and regulatory T cell biology. In 2008, he received the best overall research award at the National Student Research Forum, and in 2011 he was nominated as a Future Leader in Cancer Research by the American Association for Cancer Research. Taylor received both his M.D. and Ph.D. degrees from the Sheila and David Fuente Program in Cancer Biology at the University of Miami Miller School of Medicine. He received his B.A. in Biology from Bucknell University.
Clay Siegall, PhD
President, Chief Executive Officer and Chairman of the Board of Immunome, Inc.
Dr. Clay Siegall is the President, Chief Executive Officer and Chairman of the Board of Immunome, Inc. (Nasdaq: IMNM). With a distinguished career in leadership and drug development, he has significantly contributed to the pharmaceutical industry, including spearheading the establishment of antibody-drug conjugates as a backbone of cancer therapy in many indications. Previously, Dr. Siegall held the positions of Chief Executive Officer, President, and Chairman of the Board at Seagen Inc. (formerly Seattle Genetics, Inc.). He was the founder of Seattle Genetics, established in 1998, where he guided the company to prominence as a pharmaceutical leader, particularly in the development of antibody-drug conjugates for cancer therapy. Prior to founding Seattle Genetics, Dr. Siegall held numerous leadership positions at Bristol Myers Squibb’s Pharmaceutical Research Institute and the National Cancer Institute. Dr. Siegall holds a Ph.D. in Genetics from George Washington University as well as a B.S. in Zoology from the University of Maryland.
Daniel Baker, MD
Chief Executive Officer, Kira Biotech
Dr. Baker has over 20 years of drug development experience in the pharmaceutical industry. He currently serves as the interim Chief Development Officer at Cue Biopharma. He has also served as Chief Executive Officer and Founder of KiRa Biotech Pty Ltd., a biotechnology company, and as Venture Partner at OneVentures Investments Australia, a venture capital firm, since 2019. From 2000 to 2019, he served as Vice President, Immunology R&D at Johnson & Johnson (Janssen/Centocor) where he oversaw clinical development of Remicade, Simponi and Stelara and contributed to more than 15 regulatory approvals in the US, Europe and Japan. Following his retirement from Janssen in 2019, Dr. Baker served as CEO and founder of Kira Therapeutics and more recently as Executive Director on the board of Galapagos Therapeutics from April 2022 until October 2024. Dr. Baker received his Medical Degree from the University of Pennsylvania and completed his Medical Residency at Hershey Medical Center and Fellowship in Rheumatology and Immunology at the University of Pennsylvania, followed by a Research Fellowship in Rheumatology at Mass General Hospital.
Mona Ashiya, PhD
Member, OrbiMed Advisors LLC
Dr. Ashiya is currently a Member at OrbiMed Advisors LLC, an investment firm, where she has served in various roles of increasing responsibility since 2010. She currently serves on the boards of directors of Disc Medicine, Inc. (NASDAQ: IRON) and several private companies. Dr. Ashiya received her B.A. from the University of California, Berkeley and her Ph.D. in Cellular, Molecular and Developmental Biology from the University of Pittsburgh.